复方苦参注射液联合GP方案治疗晚期非小细胞肺癌的临床观察资料.docVIP

复方苦参注射液联合GP方案化疗治疗晚期非小细胞肺癌的临床观察 Clinical observation of compound matrine injection combined chemotherapy on treating non-small cell lung cancer 宋洋 （山东省枣庄市市中区人民医院肿瘤科，山东 枣庄，277100） 【摘要】 目的 观察复方苦参注射液联合GP（吉西他滨+顺铂）方案治疗晚期非小细胞肺癌（NSCLC）的近期疗效、生活质量变化、毒副反应及疼痛缓解情况。方法 将60例晚期NSCLC患者随机分为治疗组（复方苦参注射液+GP方案化疗）和对照组（GP方案化疗）。对照组应用吉西他滨1000mg/㎡分别于第1、8天静滴，顺铂25mg/㎡,第1、2、3天静滴；治疗组在化疗同时加用复方苦参注射液20ml，静脉滴注，1次/天，连用2周，3周为一周期，连续治疗两个周期。结果 治疗组临床获益率（CR+PR+SD）86.7%,对照组临床获益率63.3%，差异有显著性（P0.05）；两组治疗后Karonfsky评分提高率分别为73.3%和43.3%差异有显著性（P0.05）；两组在白细胞下降、恶心、呕吐、肝功能损害方面比较统计学有显著差异性（P0.05）,在血小板下降、血红蛋白下降、肾功能损害方面比较统计学无显著差异性（P0.05）；治疗组止痛缓解率90.0%高于对照组63.3%，两组差异有显著性（P0.05）。结论 复方苦参注射液联合GP方案化疗治疗中晚期非小细胞肺癌可明显改善患者生活质量、减轻化疗毒副作用、缓解轻中度疼痛。 【关键词】复方苦参注射液；非小细胞肺癌；化疗；毒副反应 【 Abstract 】 Objective To observe the traditional Chinese medicine compound matrine injection combined GP (gemcitabine plus cisplatin) scheme for treatment of advanced non-small cell lung cancer (NSCLC), recent curative effect, life quality changes, adverse reaction and pain relief. Methods 60 cases of advanced non-small cell lung cancer (NSCLC) patients were randomly divided into treatment group (compound sophora injection + GP chemotherapy) scheme and control scheme of chemotherapy (GP). Control application of gemcitabine 1000 mg / ㎡ in 8 days, the static drop 1, cisplatin, 25 mg / ㎡, 1, 2, 3 days static drops; Treatment group at the same time in the chemotherapy combined with compound sophora injection 20 ml, intravenous drip, 1 time/day, stay two weeks, three weeks for a cycle, continuous treatment of two cycles. Results The treatment group clinical benefit rate (CR + PR + SD) 86.7%, control group clinical benefit rate is 63.3%, with significant difference (P 0.05); Karonfsky score increase rate of the two groups after treatment with significant difference at 73.3% and 43.3% respectively (P 0.05); In the two groups in white blood cells decline, nausea, vomiting, liver function damage are statistically significant differences (P 0.05), the fall in plat